Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
BCAX Stock Chart & Stats
$21.12
-$0.31(-1.97%)
At close: 4:00 PM EST
$21.12
-$0.31(-1.97%)
Day’s Range― - ―
52-Week Range$7.80 - $22.01
Previous CloseN/A
Volume80.52K
Average Volume (3M)595.33K
Market Cap
$1.38B
Enterprise Value$1.06B
Total Cash (Recent Filing)$414.80M
Total Debt (Recent Filing)$1.71M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding65,467,186
10 Day Avg. Volume640,303
30 Day Avg. Volume595,333
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.29
Price to Sales (P/S)0.00
P/FCF Ratio-8.59
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.03
Forecast
1Y Price Target
$29.33Price Target Upside38.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DifferentiationHigh confirmed response rates, deeper tumor responses linked to immune pathway activation, and comparative data showing stronger complete responses versus a key rival suggest potential best‑in‑class positioning if results are replicated in later trials.
Financial Runway And Commercial ReadinessA substantial cash position paired with planned senior commercial hires, including a chief commercial officer, provides funding visibility for development milestones and builds launch readiness for a possible approval.
Phase 3 Advancement And Accelerated Approval PotentialAdvancement into the pivotal Phase 3 with a selected 1500 mg induction regimen and strong enrollment momentum could enable an interim objective response analysis that supports an accelerated approval filing if efficacy is sustained.
Bears Say
Interim Analysis Limitations And Reliance On Long‑term SurvivalAn interim analysis restricted to a subset with limited unblinding, coupled with confirmatory approvals dependent on full overall survival follow‑up, raises the risk that later data may not validate early response signals.
Regulatory And Dosing UncertaintyUncertainty about the final less‑frequent maintenance dose and ongoing discussions with regulators could complicate late‑stage plans and create ambiguity around the eventual label and dosing recommendations.
Safety Concerns And Competitive PressureTGF‑beta related tolerability issues and higher dose toxicities observed in some cohorts, together with the threat of a competing therapy reaching the market sooner, could hinder physician adoption and limit commercial uptake.
Bicara Therapeutics Inc. News
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $7.80 and its highest was $22.01 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $1.38B.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s upcoming earnings report date is May 19, 2026 which is in 36 days.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Mar 30, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.672 by -$0.008.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 65,467,186 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.672. Following the earnings report the stock price went up 3.647%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicara Therapeutics Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.33 (38.87% Upside)
$29.33 (38.87% Upside)
Blogger Sentiment
Bullish
BCAX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.07%
12-Months-Change
Fundamentals
Return on Equity
-32.49%
Trailing 12-Months
Asset Growth
-7.01%
Trailing 12-Months
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
BCAX Company Deck
BCAX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory momentum: Breakthrough Therapy Designation, selection of a pivotal dose (1,500 mg weekly), robust Phase Ib durability and survival data (DOR ~21.7 months; OS ~21.3 months; DOR >3x vs pembro+chemotherapy), advancement into Phase III with an interim analysis mid-2027, and an oversubscribed financing that extends runway into H1 2029. Key risks discussed include rising operating expenses, reliance on interim analysis and regulatory alignment for accelerated approval, enrollment/execution risk for the pivotal and bridging studies, and clinical uncertainty in exploratory indications (e.g., colorectal cancer). On balance, the call emphasized de-risking milestones and readiness for next-phase development, while acknowledging operational and regulatory dependencies.View all BCAX earnings summariesBCAX Stock 12 Month Forecast
Average Price Target
$29.33
▲(38.87% Upside)
Technical Analysis
Arbutus Biopharma
―
Bicycle Therapeutics
―
Relay Therapeutics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
22.54% Insiders
13.71% Mutual Funds
49.69% Other Institutional Investors
6.15% Public Companies and
Individual Investors